Improve clinical care with AI

Improve clinical care with AI

Digitise and analyze all your clinical documentation

Get Started today

Proven Results Scientifically Validated AI.

Proven Results Scientifically Validated AI.

Proven Results Scientifically Validated AI.

Our core AI modules have been independently validated for safety and impact.

100%

Safe, hallucination-free note generation

9.1/10

Meaningfulness assessed by independent clinicians

79%

Reduction in documentation time

Reduction in documentation time per doctor

Learn more

AI That Adapts to Every Clinical Setting

AI That Adapts to Every Clinical Setting

AI That Adapts to Every Clinical Setting

Our modular, scientifically validated core modules scale across diverse clinical workflows.

Note -1

File -1

File -2

Note -2

DISCHARGE SUMMARY

Diagnosis

Primary Refractory DLBC (Diffuse Large B-Cell Lymphoma)

Reason for Admission

Re-apheresis + C1D15 Glofitamab

Age/Sex:

17-year-old Male

Comorbidities

Diabetes Mellitus (Diabetic), Hypertension (HTN)

Family History (F/H):

Sister had breast carcinoma

Automate Discharge Summaries

Generate comprehensive, accurate discharge summaries in seconds - seamlessly pulling patient details at the click of a button.

Learn more

Fast-track Clinical Trials

Capture case record data automatically, refer to protocol guidelines, and reduce compliance errors with real-time alerts

Learn more

Transcript


APML Low Risk under evaluation


Started on ATRA (10mg) 4-0-3 since 15.4.25 - 18.4.25 (wef 20.1.25 in TMH)

ATO wef 19.4.25

Diagnostic samples sent today


Currently

No bleeding manifestations

c/o blurring of vision


Afebrile


VITALS

T 98F

PR 80/min

BP 110/70

sPO2 99% RA

RR 20/min

CVS: S1S2+ No murmurs

RS: Clear

PA: NAD


Labs (E)

Hb 12.6

Plt 60

TC 7.88

ANC 6.33

M 2.3

Na 137

K 3.45

Ca 9.47

P 3.72

Mg 1.81

Fibrinogen 144


PICC inserted today

Check Cxray done

Position verified


Baseline weight 51 kg

Weight today 50 kg


ECG QTc 421ms


NCCT thorax NAD


PLAN

1. Inj ATO 8mg IV D3

2. ⁠C ATRA 10mg 2-0-2 D2(D7 total)

3. ⁠T Sevelamer 400 mg TDS

4. ⁠5U Cryo TDS

5. ⁠1 SDP BD -HOLD

6. ⁠T Protrate 10 mg TDS

7. ⁠C Hydrea 1000 mg 1-1-1


Tumour Board Treatment plan

Patient Details

Parameter

Value

Age

48

Sex

Male

Date of Presentation

October 20, 2025

Extracted Text

Patient is a retired veteran presenting with a chief complaint of numbness in his left leg, from the knee down to the foot, for the past 3 days. Initially, he experienced a tingling sensation, which progressed to complete numbness. The numbness is affecting his daily activities, particularly walking, and he is concerned about falling. He reports no pain or weakness in the leg
Patient’s past medical history includes diabetes, hypertension, and sinusitis. He is taking metformin, lisinopril, and fluticasone as prescribed. He has noticed an increase in his blood sugar levels recently and had a bad episode of sinusitis…

Afebrile

Additional information

Based on the patient’s symptoms and physical examination, diabetic neuropathy is suspected as a complication of his diabetes. Elevated blood pressure and

Transcript


APML Low Risk under evaluation


Started on ATRA (10mg) 4-0-3 since 15.4.25 - 18.4.25 (wef 20.1.25 in TMH)

ATO wef 19.4.25

Diagnostic samples sent today


Currently

No bleeding manifestations

c/o blurring of vision


Afebrile


VITALS

T 98F

PR 80/min

BP 110/70

sPO2 99% RA

RR 20/min

CVS: S1S2+ No murmurs

RS: Clear

PA: NAD


Labs (E)

Hb 12.6

Plt 60

TC 7.88

ANC 6.33

M 2.3

Na 137

K 3.45

Ca 9.47

P 3.72

Mg 1.81

Fibrinogen 144


PICC inserted today

Check Cxray done

Position verified


Baseline weight 51 kg

Weight today 50 kg


ECG QTc 421ms


NCCT thorax NAD


PLAN

1. Inj ATO 8mg IV D3

2. ⁠C ATRA 10mg 2-0-2 D2(D7 total)

3. ⁠T Sevelamer 400 mg TDS

4. ⁠5U Cryo TDS

5. ⁠1 SDP BD -HOLD

6. ⁠T Protrate 10 mg TDS

7. ⁠C Hydrea 1000 mg 1-1-1


Tumour Board Treatment plan

Patient Details

Parameter

Value

Age

48

Sex

Male

Date of Presentation

October 20, 2025

Extracted Text

Patient is a retired veteran presenting with a chief complaint of numbness in his left leg, from the knee down to the foot, for the past 3 days. Initially, he experienced a tingling sensation, which progressed to complete numbness. The numbness is affecting his daily activities, particularly walking, and he is concerned about falling. He reports no pain or weakness in the leg
Patient’s past medical history includes diabetes, hypertension, and sinusitis. He is taking metformin, lisinopril, and fluticasone as prescribed. He has noticed an increase in his blood sugar levels recently and had a bad episode of sinusitis…

Afebrile

Additional information

Based on the patient’s symptoms and physical examination, diabetic neuropathy is suspected as a complication of his diabetes. Elevated blood pressure and

Transcript


APML Low Risk under evaluation


Started on ATRA (10mg) 4-0-3 since 15.4.25 - 18.4.25 (wef 20.1.25 in TMH)

ATO wef 19.4.25

Diagnostic samples sent today


Currently

No bleeding manifestations

c/o blurring of vision


Afebrile


VITALS

T 98F

PR 80/min

BP 110/70

sPO2 99% RA

RR 20/min

CVS: S1S2+ No murmurs

RS: Clear

PA: NAD


Labs (E)

Hb 12.6

Plt 60

TC 7.88

ANC 6.33

M 2.3

Na 137

K 3.45

Ca 9.47

P 3.72

Mg 1.81

Fibrinogen 144


PICC inserted today

Check Cxray done

Position verified


Baseline weight 51 kg

Weight today 50 kg


ECG QTc 421ms


NCCT thorax NAD


PLAN

1. Inj ATO 8mg IV D3

2. ⁠C ATRA 10mg 2-0-2 D2(D7 total)

3. ⁠T Sevelamer 400 mg TDS

4. ⁠5U Cryo TDS

5. ⁠1 SDP BD -HOLD

6. ⁠T Protrate 10 mg TDS

7. ⁠C Hydrea 1000 mg 1-1-1


Tumour Board Treatment plan

Patient Details

Parameter

Value

Age

48

Sex

Male

Date of Presentation

October 20, 2025

Extracted Text

Patient is a retired veteran presenting with a chief complaint of numbness in his left leg, from the knee down to the foot, for the past 3 days. Initially, he experienced a tingling sensation, which progressed to complete numbness. The numbness is affecting his daily activities, particularly walking, and he is concerned about falling. He reports no pain or weakness in the leg
Patient’s past medical history includes diabetes, hypertension, and sinusitis. He is taking metformin, lisinopril, and fluticasone as prescribed. He has noticed an increase in his blood sugar levels recently and had a bad episode of sinusitis…

Afebrile

Additional information

Based on the patient’s symptoms and physical examination, diabetic neuropathy is suspected as a complication of his diabetes. Elevated blood pressure and

Transcript


APML Low Risk under evaluation


Started on ATRA (10mg) 4-0-3 since 15.4.25 - 18.4.25 (wef 20.1.25 in TMH)

ATO wef 19.4.25

Diagnostic samples sent today


Currently

No bleeding manifestations

c/o blurring of vision


Afebrile


VITALS

T 98F

PR 80/min

BP 110/70

sPO2 99% RA

RR 20/min

CVS: S1S2+ No murmurs

RS: Clear

PA: NAD


Labs (E)

Hb 12.6

Plt 60

TC 7.88

ANC 6.33

M 2.3

Na 137

K 3.45

Ca 9.47

P 3.72

Mg 1.81

Fibrinogen 144


PICC inserted today

Check Cxray done

Position verified


Baseline weight 51 kg

Weight today 50 kg


ECG QTc 421ms


NCCT thorax NAD


PLAN

1. Inj ATO 8mg IV D3

2. ⁠C ATRA 10mg 2-0-2 D2(D7 total)

3. ⁠T Sevelamer 400 mg TDS

4. ⁠5U Cryo TDS

5. ⁠1 SDP BD -HOLD

6. ⁠T Protrate 10 mg TDS

7. ⁠C Hydrea 1000 mg 1-1-1


Tumour Board Treatment plan

Patient Details

Parameter

Value

Age

48

Sex

Male

Date of Presentation

October 20, 2025

Extracted Text

Patient is a retired veteran presenting with a chief complaint of numbness in his left leg, from the knee down to the foot, for the past 3 days. Initially, he experienced a tingling sensation, which progressed to complete numbness. The numbness is affecting his daily activities, particularly walking, and he is concerned about falling. He reports no pain or weakness in the leg
Patient’s past medical history includes diabetes, hypertension, and sinusitis. He is taking metformin, lisinopril, and fluticasone as prescribed. He has noticed an increase in his blood sugar levels recently and had a bad episode of sinusitis…

Afebrile

Additional information

Based on the patient’s symptoms and physical examination, diabetic neuropathy is suspected as a complication of his diabetes. Elevated blood pressure and

Transcript


APML Low Risk under evaluation


Started on ATRA (10mg) 4-0-3 since 15.4.25 - 18.4.25 (wef 20.1.25 in TMH)

ATO wef 19.4.25

Diagnostic samples sent today


Currently

No bleeding manifestations

c/o blurring of vision


Afebrile


VITALS

T 98F

PR 80/min

BP 110/70

sPO2 99% RA

RR 20/min

CVS: S1S2+ No murmurs

RS: Clear

PA: NAD


Labs (E)

Hb 12.6

Plt 60

TC 7.88

ANC 6.33

M 2.3

Na 137

K 3.45

Ca 9.47

P 3.72

Mg 1.81

Fibrinogen 144


PICC inserted today

Check Cxray done

Position verified


Baseline weight 51 kg

Weight today 50 kg


ECG QTc 421ms


NCCT thorax NAD


PLAN

1. Inj ATO 8mg IV D3

2. ⁠C ATRA 10mg 2-0-2 D2(D7 total)

3. ⁠T Sevelamer 400 mg TDS

4. ⁠5U Cryo TDS

5. ⁠1 SDP BD -HOLD

6. ⁠T Protrate 10 mg TDS

7. ⁠C Hydrea 1000 mg 1-1-1


Tumour Board Treatment plan

Patient Details

Parameter

Value

Age

48

Sex

Male

Date of Presentation

October 20, 2025

Extracted Text

Patient is a retired veteran presenting with a chief complaint of numbness in his left leg, from the knee down to the foot, for the past 3 days. Initially, he experienced a tingling sensation, which progressed to complete numbness. The numbness is affecting his daily activities, particularly walking, and he is concerned about falling. He reports no pain or weakness in the leg
Patient’s past medical history includes diabetes, hypertension, and sinusitis. He is taking metformin, lisinopril, and fluticasone as prescribed. He has noticed an increase in his blood sugar levels recently and had a bad episode of sinusitis…

Afebrile

Additional information

Based on the patient’s symptoms and physical examination, diabetic neuropathy is suspected as a complication of his diabetes. Elevated blood pressure and

Transcript


APML Low Risk under evaluation


Started on ATRA (10mg) 4-0-3 since 15.4.25 - 18.4.25 (wef 20.1.25 in TMH)

ATO wef 19.4.25

Diagnostic samples sent today


Currently

No bleeding manifestations

c/o blurring of vision


Afebrile


VITALS

T 98F

PR 80/min

BP 110/70

sPO2 99% RA

RR 20/min

CVS: S1S2+ No murmurs

RS: Clear

PA: NAD


Labs (E)

Hb 12.6

Plt 60

TC 7.88

ANC 6.33

M 2.3

Na 137

K 3.45

Ca 9.47

P 3.72

Mg 1.81

Fibrinogen 144


PICC inserted today

Check Cxray done

Position verified


Baseline weight 51 kg

Weight today 50 kg


ECG QTc 421ms


NCCT thorax NAD


PLAN

1. Inj ATO 8mg IV D3

2. ⁠C ATRA 10mg 2-0-2 D2(D7 total)

3. ⁠T Sevelamer 400 mg TDS

4. ⁠5U Cryo TDS

5. ⁠1 SDP BD -HOLD

6. ⁠T Protrate 10 mg TDS

7. ⁠C Hydrea 1000 mg 1-1-1


Tumour Board Treatment plan

Patient Details

Parameter

Value

Age

48

Sex

Male

Date of Presentation

October 20, 2025

Extracted Text

Patient is a retired veteran presenting with a chief complaint of numbness in his left leg, from the knee down to the foot, for the past 3 days. Initially, he experienced a tingling sensation, which progressed to complete numbness. The numbness is affecting his daily activities, particularly walking, and he is concerned about falling. He reports no pain or weakness in the leg
Patient’s past medical history includes diabetes, hypertension, and sinusitis. He is taking metformin, lisinopril, and fluticasone as prescribed. He has noticed an increase in his blood sugar levels recently and had a bad episode of sinusitis…

Afebrile

Additional information

Based on the patient’s symptoms and physical examination, diabetic neuropathy is suspected as a complication of his diabetes. Elevated blood pressure and

Transcript


APML Low Risk under evaluation


Started on ATRA (10mg) 4-0-3 since 15.4.25 - 18.4.25 (wef 20.1.25 in TMH)

ATO wef 19.4.25

Diagnostic samples sent today


Currently

No bleeding manifestations

c/o blurring of vision


Afebrile


VITALS

T 98F

PR 80/min

BP 110/70

sPO2 99% RA

RR 20/min

CVS: S1S2+ No murmurs

RS: Clear

PA: NAD


Labs (E)

Hb 12.6

Plt 60

TC 7.88

ANC 6.33

M 2.3

Na 137

K 3.45

Ca 9.47

P 3.72

Mg 1.81

Fibrinogen 144


PICC inserted today

Check Cxray done

Position verified


Baseline weight 51 kg

Weight today 50 kg


ECG QTc 421ms


NCCT thorax NAD


PLAN

1. Inj ATO 8mg IV D3

2. ⁠C ATRA 10mg 2-0-2 D2(D7 total)

3. ⁠T Sevelamer 400 mg TDS

4. ⁠5U Cryo TDS

5. ⁠1 SDP BD -HOLD

6. ⁠T Protrate 10 mg TDS

7. ⁠C Hydrea 1000 mg 1-1-1


Tumour Board Treatment plan

Patient Details

Parameter

Value

Age

48

Sex

Male

Date of Presentation

October 20, 2025

Extracted Text

Patient is a retired veteran presenting with a chief complaint of numbness in his left leg, from the knee down to the foot, for the past 3 days. Initially, he experienced a tingling sensation, which progressed to complete numbness. The numbness is affecting his daily activities, particularly walking, and he is concerned about falling. He reports no pain or weakness in the leg
Patient’s past medical history includes diabetes, hypertension, and sinusitis. He is taking metformin, lisinopril, and fluticasone as prescribed. He has noticed an increase in his blood sugar levels recently and had a bad episode of sinusitis…

Afebrile

Additional information

Based on the patient’s symptoms and physical examination, diabetic neuropathy is suspected as a complication of his diabetes. Elevated blood pressure and

Transcript

History of Presenting Illness


Sharp, stabbing pain in lower back. Difficulty sitting for extended periods. No injury or physical activity that could have caused the

Clinical Notes

Location

Lower back.

Intensity

7/10 on a standardized pain scale (0 = no pain, 10 = worst possible pain)

Characteristics

Sharp, stabbing pain.

Impact

Difficulty sitting for extended periods.

Onset and Cause

No known injury or physical activity contributing to the pain.

Dr. Jane Foster

Use a standardized pain scale and document location, intensity, and characteristics.

Digitise OPD Consultations

Record outpatient consultations hands-free and generate structured notes using templates tailored to your specialty and workflow.

Learn more

Automate Health Registry Updates

Streamline registry management by automatically extracting and updating longitudinal patient data across multiple file types

Learn more

Your Data is Secure

Your Data is Secure

Your Data is Secure

We prioritize the highest standards of data protection and privacy for healthcare organizations

Foster never uses your patient data for model training.

All confidential information remains strictly private and access-controlled.

End-to-end encryption safeguards your data both in transit and at rest.

FINISH YOUR

DOCUMENTATION WHILE

YOU TREAT WITH FOSTER

TRY FOR FREE

© 2024 by Foster AI Inc.

FINISH YOUR

DOCUMENTATION WHILE

YOU TREAT WITH FOSTER

TRY FOR FREE

© 2024 by Foster AI Inc.

FINISH YOUR

DOCUMENTATION WHILE

YOU TREAT WITH FOSTER

TRY FOR FREE

© 2024 by Foster AI Inc.

FINISH YOUR

DOCUMENTATION WHILE

YOU TREAT WITH FOSTER

TRY FOR FREE

© 2024 by Foster AI Inc.